Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001503802-26-000023
Filing Date
2026-04-13
Accepted
2026-04-13 08:23:13
Documents
19
Period of Report
2026-04-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A kpti-20260413.htm   iXBRL DEF 14A 2033389
2 GRAPHIC img118964590_0.jpg GRAPHIC 83422
3 GRAPHIC img118964590_1.gif GRAPHIC 2558
4 GRAPHIC img118964590_2.jpg GRAPHIC 83422
5 GRAPHIC img118964590_3.gif GRAPHIC 59197
6 GRAPHIC img118964590_4.gif GRAPHIC 57042
7 GRAPHIC img118964590_5.jpg GRAPHIC 524763
8 GRAPHIC img118964590_6.jpg GRAPHIC 544027
  Complete submission text file 0001503802-26-000023.txt   5991328

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20260413.xsd EX-101.SCH 29988
22 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20260413_htm.xml XML 141719
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36167 | Film No.: 26856528
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)